Pieris Pharmaceuticals Presents Positive Preclinical Data on Lead Bispecific Immuno-Oncology Program
Tumor-targeting CD137/HER2 Bispecifics Exhibit Desired Drug-Like Properties and Tumor-Dependent T Cell Activation […]
Tumor-targeting CD137/HER2 Bispecifics Exhibit Desired Drug-Like Properties and Tumor-Dependent T Cell Activation […]
Wall Street Analyzer’s CEO Interview Series […]
Up to $9.5 Million in Debt Financing and $12 Million in Equity Financing.
Company to Advance its Immuno-Dermatology and Inflammatory Bowel Disease Product Candidates
Lead Compound Bertilimumab, First-in-Class Autoimmune Therapy, a Priority
[…]
Will Also Participate in Additional Wattenberg Well […]
Wall Street Analyzer’s CEO Interview Series […]
(CSE: MRM, OTCQX: MMTIF) […]
Copyright © 2019 The Wall Street Analyst, LLC. All rights reserved. Website by MyWebsiteSpot.com